Natural killer cells offer hope for hard-to-treat pediatric sarcomas

There is a five-year survival rate of approximately 20% for patients in advanced stages of disease.

The new therapeutic strategy uses engineered immune cells, called natural killer cells, to target and destroy sarcoma tumors.

The treatment could also have an impact on other hard-to-cure diseases such as triple negative breast cancer.

Clinical Director at UQ’s Ian Frazer Centre for Children’s Immunotherapy Research and Director of Oncology Services at Queensland Children’s Hospital, Associate Professor Wayne Nicholls, said the research was very promising and addressed an unmet need.

“Sarcoma is the biggest killer of people aged 10 to 30,”‘ he said.

“These cancers are harder to treat with a poorer prognosis and there has been no improvement in survival for 40 years.

“At the moment, there are really no novel therapies available for pediatric solid tumors. This is a significant step forward towards a novel therapy that could be used for patients.”‘

The study was a collaboration of researchers from UQ, Queensland Children’s Hospital, University of New South Wales and The University of Otago.

The research is published in Clinical and Translational Medicine.

More information:
Pui Yeng Lam et al, Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR, Clinical and Translational Medicine (2025). DOI: 10.1002/ctm2.70140